0001225208-24-002104.txt : 20240214 0001225208-24-002104.hdr.sgml : 20240214 20240214183645 ACCESSION NUMBER: 0001225208-24-002104 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240212 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wolk Joseph J CENTRAL INDEX KEY: 0001744564 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 24641275 MAIL ADDRESS: STREET 1: JOHNSON & JOHNSON STREET 2: ONE JOHNSON & JOHNSON PLAZA CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 4 1 doc4.xml X0508 4 2024-02-12 0000200406 JOHNSON & JOHNSON JNJ 0001744564 Wolk Joseph J ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 1 Exec VP, CFO 0 Common Stock 2024-02-12 4 M 0 22119.0000 0.0000 A 74983.0000 D Common Stock 2024-02-12 4 M 0 3716.0000 0.0000 A 78699.0000 D Common Stock 2024-02-12 4 F 0 10816.0000 157.4000 D 67883.0000 D Common Stock 2048.0000 I By 401k Performance Share Units 2024-02-12 4 M 0 22119.0000 0.0000 D 2024-02-08 Common Stock 22119.0000 0.0000 D Awarded under Issuer's Long-Term Incentive Plan. Performance Share Units awarded on February 8, 2021; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board on February 12, 2024. Shares earned due to performance factor of 116.8% upon certification of performance results by the Board. Shares withheld for payment of taxes upon vesting of Performance Share Units and certification of performance results by the Board. Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2024). /s/ Raavi K. Deol, as attorney-in-fact for Joseph J. Wolk 2024-02-14